Publications and Guidelines


Convalescent Plasma to Limit Coronavirus Associated Complications: An Open Label, Phase 2A Study of High-Titer Anti-SARS-CoV-2 Plasma in Hospitalized Patients With COVID-19

Open label, single arm trial with covalescent plasma, 1-2 units with anti-CoV2 titer >1:64. Endpoint: RNA Change, ICU admision, hospital Mortality, Hospital Lenthg

#treatment #ICU

Temporal profiles of viral load in posterior oropharyngeal saliva samples and serum antibody responses during infection by SARS-CoV-2: an observational cohort study

Patients shed virus in saliva more than 21 days after disease onset, Peak Viral load is positive correlated with age and is independent from disease severity. The vast majority of patients develop antibodies with neutralizing activity in vitro.

#diagnosis #general